中國生物科技服務(8037.HK)股價創近11年新高 上海隆耀的研究論文獲巴克萊在研報中提及
格隆匯2月9日丨近日,巴克萊發佈行業研報,其中提及了中國生物科技服務(8037.HK)旗下子公司上海隆耀生物科技有限公司及其首席科學家楊選明教授關於CD20-CART-OX40的研究論文。
論文指出,OX40能夠增強CAR-T細胞的效能。5名患者中有3名其體內的CAR-T細胞數量在峯值時達到了注射細胞數量的100倍及以上,並且沒有觀察到與之相關的安全問題。從注射後的第14天到第107天,4名患者表現出了轉移性腫瘤的顯著減少,2名患者在接受CAR-T細胞治療後獲得完全緩解,3名患者獲得部分緩解,客觀有效率達到100%。實驗證明獨立於整合CAR結構及抗原激活的OX40共刺激信號是維持CAR-T活性的關鍵要素。
注:中國生物科技服務近日持續上漲,並於今日盤中高見2.6港元創2010年6月15日以來近11年新高,今年迄今已累漲超75%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.